Immunocore (IMCR) vs Mesoblast (MESO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Mesoblast (MESO) has outperformed Immunocore (IMCR) over the past year, losing 29.1% versus a loss of 32.9%. Over five years, MESO leads with a -12.0% price change compared with -27.4% for IMCR. Mesoblast is the larger company by market cap ($1.41 billion vs $1.36 billion), about 1.0 times the size.
Immunocore converts more of its revenue into profit, with a net margin of -8.9% versus -593.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | MESO |
|---|---|---|
| Share price | $26.41 | $10.89 |
| Market cap | $1.36B | $1.41B |
| 1-day change | -0.83% | -2.59% |
| YTD return | -23.91% | -39.63% |
| 1-year return | -32.88% | -29.15% |
| 5-year return | -27.41% | -12.04% |
| Forward P/E | — | 31.11 |
| EPS (TTM) | $-0.64 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $400.02M | $17.20M |
| Revenue growth (YoY) | +28.95% | +191.39% |
| Net income (latest FY) | $-35.51M | $-102.14M |
| Gross margin | 98.73% | 70.17% |
| Operating margin | -11.34% | — |
| Net margin | -8.88% | -593.92% |
| 52-week high | $40.72 | $21.50 |
| 52-week low | $25.61 | $10.87 |
| Distance from 52-week high | -35.13% | -49.35% |
| Analyst consensus | buy | none |
| Avg. price target upside | +124.54% | +239.76% |
| Average volume | 450.88K | 240.68K |
| Shares outstanding | 51.68M | 129.85M |
| Employees | 524 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Immunocore is more profitable, keeping -8.9 cents of every revenue dollar as net income versus -593.9 cents for Mesoblast.
- Mesoblast grew revenue faster in its latest fiscal year (+191.39% vs +28.95%).
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
IMCR vs MESO FAQ
Which is bigger, Immunocore or Mesoblast?
Mesoblast (MESO) is larger, with a market capitalization of $1.41B compared with $1.36B for Immunocore (IMCR).
Which stock has performed better over the past year, IMCR or MESO?
MESO returned -29.15% over the past 12 months, compared with -32.88% for IMCR (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and Mesoblast in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.